期刊文献+

合并消化道癌的胃肠间质瘤21例临床病理及免疫组织化学分析 被引量:4

Clinicopathologic and Immunohistochemical Analysis of 21 Cases of Coexistence of Gastrointestinal Stromal Tumors with Primary Gastrointestinal Carcinoma
下载PDF
导出
摘要 目的分析胃肠间质瘤(GIST)合并消化道癌的临床病理特征及免疫组织化学(免疫组化)表型。方法回顾分析合并消化道癌的GIST 21例的临床病理特征及随访资料,部分病例补充完善CD117、DOG-1、CD34、Vimentin、Actin、S-100、EGFR、VEGF、Ki-67免疫组化检查。结果合并消化道癌的GIST以60岁以上男性多见,发生部位以胃体最常见,本组发生在胃体12例,胃底5例,肠道3例,食管1例;合并胃体腺癌12例,食管鳞癌5例,结肠腺癌2例,十二指肠腺癌、空肠腺癌各1例。除消化道癌的常见症状外,均无其他特异性症状,术前GIST均漏诊。免疫表型:CD117、DOG-1、Vimentin阳性率为100%(21/21),CD34为94.4%(19/21),EGFR、VEGF、Ki-67分别为19.0%(4/21)、28.6%(6/21)、23.8%(5/21)。2例Actin和1例S-100灶性区域阳性。GIST危险度分级:极低危7例,低危10例,中危3例,高危1例。随访1~5年,死亡11例(52.4%),均因消化道癌转移及复发死亡。结论伴发消化道癌的GIST较单发GIST恶性程度低,危险度分级以极低度、低度危险为主,预后主要与消化道癌有关。 Objective To investigate the clinicopathologic characteristics and immunohistochemical expression of coexistence of gastrointestinal stromal tumors (GIST) with other primary gastrointestinal carcinoma. Methods The clinicopathologic and follow-up data of 21 patients with GIST complicated with gastrointestinal carcinoma were retrospectively studied. The expression of CD117, DOG-1, CD34, Vimentin, Actin, S-100, EGFR, VEGF and Ki-67 were detected by immunohistochemica] method in some patients with GISTs. Results 21 patients with GIST were mostly males over the age of 60 and the outgrowth mostly occurred in the gastric body, and the numbers in gastric body, gastric fundus, intestine and esophagus were 12, 5, 3 and 1 respectively. Among them, the numbers of coexistence of GIST with gastric adenocarcinoma, esophageal squamous cell carcinoma, colonic adenocarcinoma, duodenal adenocarcinoma and jejunal adenocarcinoma were 12, 5, 2, 1 and 1. No one had specific symptoms except common symptoms of gastrointestinal cancer and none of the GIST combined with gastrointestinal carcinoma had final diagnosis or suspected diagnosis before operation. All of the positive rates of CD117, DOG-l, Vimentin were 100% (21/21). The positive rates of CD34, EGFR, VEGF and Ki-67 were 94.4% (19/21), 19.0% (4/21), 28.6% (6/21) and 23.8% (5/21). The numbers of focal positive patients of Actin and S-100 were 2 and 1. The numbers of patients at extremely low, low, moderate and high risks were 7, 10, 3 and 1. All patients were followed-up for 1-5 years, 11 patients died of relapse or metastasis of gastrointestinal carcinoma (52.4%). Conclusion The risk factors of complicated GIST are lower than that of simple GIST, with very low and low on the scales. The prognosis is related to primary gastrointestinal carcinoma.
出处 《临床误诊误治》 2011年第12期71-73,F0003,共4页 Clinical Misdiagnosis & Mistherapy
基金 山东省医药卫生科技发展项目(2009HZ111)
关键词 胃肠道间质肿瘤 消化系统肿瘤 病理学 临床 免疫表型分型 Gastrointestinal stromal tumor Digestive system neoplasm Pathology, clinical Immunophenotyping
  • 相关文献

参考文献21

二级参考文献107

共引文献212

同被引文献35

  • 1赵锐,万谦益,王勇,崔亚平,伍羽韬,伍晓汀.胃肠间质瘤伴肝转移的临床病理特征及预后分析[J].中华转移性肿瘤杂志,2020(1):16-19. 被引量:3
  • 2Gold JS, van der Zwan SM, Gonen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors [J]. Ann Surg Oncol,2007,14 ( 1 ) : 134-142.
  • 3Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up [ J]. Ann Oncol,2009, Suppl 4:64-67.
  • 4Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1 ) [J]. Eur J Cancer,2009,45(2) :228-247.
  • 5National Institutes of Health. Common Terminology Criteria for Adverse Events Verson 3.0 [EB/OL].2003 [ 2011-11-10]. http ://etep. cancer, gov/protocolDevelopment/electronic_ applications/ctc, htm.
  • 6DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival [ J]. Ann Surg,2000,231 (1) :51-58.
  • 7Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c - kit in human gastrointestinal stromal tumors [ J ]. Science, 1998,279 (5350) :577-580.
  • 8Verweij J, Casali PG, Zalcberg J, et al. Progression- free survival in gastrointestinal stromal tumours with high - dose imatinib: randomised trial [ J ]. Lancet,2004,364 ( 9440 ) : 1127-1134.
  • 9Zalcberg JR,Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg [J]. Eur J Cancer,41 (12) :1751-1757.
  • 10Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors : a meta- analysis of 1,640 patients [ J]. J Clin Oncol,2010,28 (7) :1247- 1253.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部